Further insights in the mechanisms of interleukin-1β stimulation of osteoprotegerin in osteoblast-like cells

Journal of Bone and Mineral Research

Volumn 22, Issue 9, 2007, Pages 1350-1361

  Lambert, Cécile ^a   Oury, Cécile ^a   Dejardin, Emmanuel ^a   Chariot, Alain ^a   Piette, Jacques ^a   Malaise, Michel ^a   Merville, Marie Paule ^a   Franchimont, Nathalie ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Apoptosis; Interleukin 1 ; NF B; Osteoblast; Osteoprotegerin

Indexed keywords

3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; CYCLOHEXIMIDE; DACTINOMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; OSTEOPROTEGERIN; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; PRIMER DNA;

APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SPECIFICITY; HUMAN; HUMAN CELL; OSTEOLYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BIOSYNTHESIS; ENZYME ACTIVATION; METABOLISM; NUCLEOTIDE SEQUENCE; TUMOR CELL LINE;

APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; CELL LINE, TUMOR; DNA PRIMERS; ENZYME ACTIVATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-1BETA; MITOGEN-ACTIVATED PROTEIN KINASES; OSTEOPROTEGERIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING;

EID: 36048970815     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.070508     Document Type: Article

References (47)

1. Walsh MC, Choi Y 2003 Biology of the TRANCE axis. Cytokine Growth Factor Rev 14:251-263.
2. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, Kelley M, Hsu H, Boyle WJ, Dunstan CR, Hu S, Lacey DL 1999 The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 145:527-538.
3. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, Rattan A, Scully S, Fletcher F, Juan T, Kelley M, Burgess TL, Boyle WJ, Polverino AJ 2000 Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 157:435-448.
4. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
5. O'Brien EA, Williams JH, Marshall MJ 2000 Osteoprotegerin ligand regulates osteoclast adherence to the bone surface in mouse calvaria. Biochem Biophys Res Commun 274:281-290.
6. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R 1997 Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 3:1285-1289.
7. Grigoriadis AE, Wang ZQ, Cecchini MG, Hofstetter W, Felix R, Fleisch HA, Wagner EF 1994 c-Fos: A key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 266:443-448.
8. Boyle WJ, Simonet WS, Lacey DL 2003 Osteoclast differentiation and activation. Nature 423:337-342.
9. Tanaka S, Nakamura K, Takahasi N, Suda T 2005 Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev 208:30-49.
10. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R, Boyle WJ 1997 Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell 89:309-319.
11. Manolagas SC, Jilka RL 1995 Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 332:305-311.
12. Hofbauer LC, Gori F, Riggs BL, Lacey DL, Dunstan CR, Spelsberg TC, Khosla S 1999 Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: Potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 140:4382-4389.
13. Hofbauer LC, Lacey DL, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S 1999 Interleukin-1beta and tumor necrosis factor-alpha, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cells. Bone 25:255-259.
14. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL 2000 The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15:2-12.
15. Hofbauer LC, Dunstan CR, Spelsberg TC, Riggs BL, Khosla S 1998 Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem Biophys Res Commun 250:776-781.
16. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, Dul E, Appelbaum ER, Eichman C, DiPrinzio R, Dodds RA, James IE, Rosenberg M, Lee JC, Young PR 1998 Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273:14363-14367.
17. Shipman CM, Croucher PI 2003 Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63:912-916.
18. Miyashita T, Kawakami A, Nakashima T, Yamasaki S, Tamai M, Tanaka F, Kamachi M, Ida H, Migita K, Origuchi T, Nakao K, Eguchi K 2004 Osteoprotegerin (OPG) acts as an endogenous decoy receptor in tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis of fibroblast-like synovial cells. Clin Exp Immunol 137:430-436.
19. Lambert C, Ribbens C, Merville M, Bours V, Malaise M, Franchimont N 2003 Identification of the signalling pathways required for interleukin-lbeta stimulation of osteoprotegerin synthesis in osteoblastic cells. J Bone Miner Res 18:SA228.
20. Pantouli E, Boehm MM, Koka S 2005 Inflammatory cytokines activate p38 MAPK to induce osteoprotegerin synthesis by MG-63 cells. Biochem Biophys Res Commun 329:224-229.
21. Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U 1997 Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11:3482-3496.
22. Jimi E, Ghosh S 2005 Role of nuclear factor-kappaB in the immune system and bone. Immunol Rev 208:80-87.
23. Relic B, Bentires-Alj M, Ribbens C, Franchimont N, Guerne PA, Benoit V, Merville MP, Bours V, Malaise MG 2002 TNF-alpha protects human primary articular chondrocytes from nitric oxide-induced apoptosis via nuclear factor-kappaB. Lab Invest 82:1661-1672.
24. Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D, Gallagher TF, Fisher S, McDonnell PC, Carr SA, Huddleston MJ, Seibel G, Porter TG, Livi GP, Adams JL, Lee JC 1997 Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 272:12116-12121.
25. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR 1995 A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA 92:7686-7689.
26. Pierce JW, Schoenleber R, Jesmok G, Best J, Moore SA, Collins T, Gerritsen ME 1997 Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo. J Biol Chem 272:21096-21103.
27. Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS 2001 c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest 108:73-81.
28. Relic B, Benoit V, Franchimont N, Ribbens C, Kaiser MJ, Gillet P, Merville MP, Bours V, Malaise MG 2004 15-deoxy-delta12,14-prostaglandin J2 inhibits Bay 11-7085-induced sustained extracellular signal-regulated kinase phosphorylation and apoptosis in human articular chondrocytes and synovial fibroblasts. J Biol Chem 279:22399-22403.
29. Olivier S, Fillet M, Malaise M, Piette J, Bours V, Merville MP, Franchimont N 2005 Sodium nitroprusside-induced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene. Biochem Pharmacol 69:891-901.
30. Bonif M, Meuwis MA, Close P, Benoit V, Heyninck K, Chapelle JP, Bours V, Merville MP, Piette J, Beyaert R, Chariot A 2006 TNFalpha- and IKKbeta-mediated TANK/I-TRAF phosphorylation: Implications for interaction with NEMO/IKKgamma and NF-kappaB activation. Biochem J 394:593-603.
31. Thirunavukkarasu K, Halladay DL, Miles RR, Yang X, Galvin RJ, Chandrasekhar S, Martin TJ, Onyia JE 2000 The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. J Biol Chem 275:25163-25172.
32. Pahl HL 1999 Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18:6853-6866.
33. Gowen M, Wood DD, Ihrie EJ, McGuire MK, Russell RG 1983 An interleukin 1 like factor stimulates bone resorption in vitro. Nature 306:378-380.
34. Hofbauer LC, Schoppet M 2004 Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490-495.
35. Strand V, Kavanaugh AF 2004 The role of interleukin-1 in bone resorption in rheumatoid arthritis. Rheumatology (Oxf) 43(Suppl 3):iii10-iii16.
36. Roodman GD 2001 Biology of osteoclast activation in cancer. J Clin Oncol 19:3562-3571.
37. Bonizzi G, Karin M 2004 The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 25:280-288.
38. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G 2003 Transcriptional activation of the NF-kappaB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 22:1313-1324.
39. Jimi E, Nakamura I, Ikebe T, Akiyama S, Takahashi N, Suda T 1998 Activation of NF-kappaB is involved in the survival of osteoclasts promoted by interleukin-1. J Biol Chem 273:8799-8805.
40. Shim J, Karin M 2002 The control of mRNA stability in response to extracellular stimuli. Mol Cells 14:323-331.
41. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA 1997 Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J 16:1909-1920.
42. Franchimont N, Reenaers C, Lambert C, Belaiche J, Bours V, Malaise M, Delvenne P, Louis E 2004 Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin Exp Immunol 138:491-498.
43. Rogers A, Eastell R 2005 Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: Clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 90:6323-6331.
44. Holen I, Croucher PI, Hamdy FC, Eaton CL 2002 Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res 62:1619-1623.
45. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET 2001 Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107:1235-1244.
46. Croucher PI, Shipman CM, Lippitt J, Perry M, Asosingh K, Hijzen A, Brabbs AC, van Beek EJ, Holen I, Skerry TM, Dunstan CR, Russell GR, Van Camp B, Vanderkerken K 2001 Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98:3534-3540.
47. Kostenuik PJ 2005 Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5:618-625.